Further clinical studies should follow to evaluate the additional benefit in risk assessment in specific CAD patient subgroups, e.g. patients with diabetes mellitus, high cholesterol or LDL-levels despite statin treatment or recurrent ischemic events by assessing Lp-PLA2 conjointly to CRP, other surrogate markers of systemic inflammation and impaired vascular wall function, including FMD and AIx. This evidence concerns the gene PLA2G7 and diabetes mellitus.